The study find that the the first glucagon therapy approved for the emergency treatment; of severe hypoglycemia that can be administer without an injection. Severe hypoglycemia occurs when a patient’s blood sugar ;levels fall to a level where he or she becomes confused or unconscious or suffers from other symptoms that require assistance from another person to treat. Typically, severe hypoglycemia occurs in people with diabetes who are using insulin treatment.
First glucagon therapy
Baqsimi is approve to treat severe hypoglycemia in patients with diabetes ages four and older. People who are living with diabetes are at risk of their blood sugar levels falling below the normal range. There are many products on the market for those who need insulin, but until now; but people suffering from a severe hypoglycemic episode had to be treat with a glucagon injection that first had to be mix in a several-step process.
This new way to administer glucagon may simplify the process, which can be critical during an episode, because especially since the patient may have lost consciousness or may be having a seizure. Therefore In those situations, we want the process to treat the suffering person to be as simple as possible.” Janet Woodcock, M.D., director, FDA’s Center for Drug Evaluation and Research Baqsimi, which is a powder administer into the nose; will come in a single-use dispenser that be give to someone suffering from a severe hypoglycemic episode.
Nasal powder glucagon
Baqsimi increases blood sugar levels in the body by stimulating the liver to release stored glucose into the bloodstream. It has the opposite effect of insulin, which lowers blood sugar levels. Injectable glucagon has been approve for use in the U.S. for several decades.The efficacy and safety of Baqsimi nasal powder glucagon to treat severe hypoglycemia is evaluate in two studies of 83 and 70 adults with diabetes, comparing a single dose of Baqsimi to a single dose of glucagon injection in causing a blood sugar response to insulin-induced hypoglycemia.
Baqsimi adequately increase blood sugar levels. In a pediatric study of 48 patients over the age of four with type 1 diabetes, similar results are observe. Baqsimi not be take by patients with pheochromocytoma; a rare tumor of adrenal gland tissue, or by patients who have insulinoma; but a tumor of the pancreas. Baqsimi should not be taken by patients with a know hypersensitivity to glucagon or the inactive ingredients found in Baqsimi; as allergic reactions may occur. Baqsimi also carries a warning that it should be use with caution by those who have been fasting for long periods, have adrenal insufficiency or have chronic hypoglycemia because these conditions result in low levels of releasable glucose in the liver.